01Pipeline

Two CRAC channel inhibitors across hospital-based and chronic treatment settings.

Auxora is a clinical-stage intravenous candidate being advanced toward a Phase 1b proof-of-concept study in PAH. A planned Phase 2b study in acute pancreatitis is subject to additional funding. CM5480 is an oral candidate in preclinical and IND-enabling development for PAH and CpcPH-HFpEF.

Explore the science

02Programs

Current development programs.

The planned Auxora Phase 1b study in PAH will evaluate CRAC channel inhibition in patients and inform development of oral CM5480 for chronic treatment.

Program progressFuture stage

Pulmonary Hypertension

AuxoraIV

Pulmonary Arterial Hypertension

Preclinical / IND-enablingPhase 1Phase 2Phase 3

IND submission anticipated 2H 2026 · Phase 1b data anticipated mid-2027

Phase 1b trial not yet initiated.

CM5480Oral

Pulmonary Arterial Hypertension

Preclinical / IND-enablingPhase 1Phase 2Phase 3

Preclinical and IND-enabling studies ongoing · IND submission anticipated mid-2027

CM5480Oral

CpcPH-HFpEF

Preclinical / IND-enablingPhase 1Phase 2Phase 3

Preclinical and IND-enabling studies ongoing · IND submission anticipated mid-2027

Acute Critical Illness

AuxoraIV

Acute Pancreatitis

Preclinical / IND-enablingPhase 1Phase 2Phase 3

CARPO Phase 2b completed · FDA-aligned design for a planned Phase 2b study · initiation subject to additional funding

Development status as of October 2026. Milestone dates are anticipated.

03Development outlook

Near-term milestones.

2H 2026Auxora PAH IND submissionAnticipated for the planned Phase 1b study

Mid-2027Auxora PAH Phase 1b dataProof-of-concept data anticipated

Mid-2027CM5480 IND submissionAnticipated in pulmonary hypertension

Phase 2bAuxora in acute pancreatitisPlanned study; initiation subject to additional funding

04Product candidates

Two candidates with complementary product profiles.

Auxora is an intravenous clinical-stage candidate for short-course treatment. CM5480 is an oral candidate in preclinical and IND-enabling development for chronic use.

Auxora

IV · clinical-stage

Zegocractin, a proprietary intravenous CRAC channel inhibitor for short-course, hospital-based treatment
Evaluated across multiple Phase 2 clinical studies
More than 350 patients exposed across the clinical program
Advancing toward a planned Phase 1b study in PAH; planned Phase 2b study in acute pancreatitis subject to additional funding

CM5480

Oral · preclinical / IND-enabling

Selective oral CRAC channel inhibitor designed for chronic treatment
Preclinical and IND-enabling development in PAH and CpcPH-HFpEF
IND submission anticipated mid-2027

Pulmonary hypertension Acute pancreatitis